91 related articles for article (PubMed ID: 17426052)
1. MAP17 overexpression is a common characteristic of carcinomas.
Guijarro MV; Leal JF; Fominaya J; Blanco-Aparicio C; Alonso S; Lleonart M; Castellvi J; Ruiz L; Ramon Y Cajal S; Carnero A
Carcinogenesis; 2007 Aug; 28(8):1646-52. PubMed ID: 17426052
[TBL] [Abstract][Full Text] [Related]
2. MAP17 enhances the malignant behavior of tumor cells through ROS increase.
Guijarro MV; Leal JF; Blanco-Aparicio C; Alonso S; Fominaya J; Lleonart M; Castellvi J; Ramon y Cajal S; Carnero A
Carcinogenesis; 2007 Oct; 28(10):2096-104. PubMed ID: 17548903
[TBL] [Abstract][Full Text] [Related]
3. Large scale genetic screen identifies MAP17 as protein bypassing TNF-induced growth arrest.
Guijarro MV; Castro ME; Romero L; Moneo V; Carnero A
J Cell Biochem; 2007 May; 101(1):112-21. PubMed ID: 17230460
[TBL] [Abstract][Full Text] [Related]
4. p38α limits the contribution of MAP17 to cancer progression in breast tumors.
Guijarro MV; Vergel M; Marin JJ; Muñoz-Galván S; Ferrer I; Ramon y Cajal S; Roncador G; Blanco-Aparicio C; Carnero A
Oncogene; 2012 Oct; 31(41):4447-59. PubMed ID: 22266858
[TBL] [Abstract][Full Text] [Related]
5. Identification and partial characterization of PDZK1: a novel protein containing PDZ interaction domains.
Kocher O; Comella N; Tognazzi K; Brown LF
Lab Invest; 1998 Jan; 78(1):117-25. PubMed ID: 9461128
[TBL] [Abstract][Full Text] [Related]
6. Profiles of prostaglandin biosynthesis in sixteen established cell lines derived from human lung, colon, prostate, and ovarian tumors.
Hubbard WC; Alley MC; McLemore TL; Boyd MR
Cancer Res; 1988 Sep; 48(17):4770-5. PubMed ID: 3409218
[TBL] [Abstract][Full Text] [Related]
7. MAP17, a ROS-dependent oncogene.
Carnero A
Front Oncol; 2012; 2():112. PubMed ID: 22973555
[TBL] [Abstract][Full Text] [Related]
8. MAP17 and the double-edged sword of ROS.
Carnero A
Biochim Biophys Acta; 2012 Aug; 1826(1):44-52. PubMed ID: 22465409
[TBL] [Abstract][Full Text] [Related]
9. Identification and partial characterization of a novel membrane-associated protein (MAP17) up-regulated in human carcinomas and modulating cell replication and tumor growth.
Kocher O; Cheresh P; Lee SW
Am J Pathol; 1996 Aug; 149(2):493-500. PubMed ID: 8701988
[TBL] [Abstract][Full Text] [Related]
10. Smad3 is overexpressed in advanced human prostate cancer and necessary for progressive growth of prostate cancer cells in nude mice.
Lu S; Lee J; Revelo M; Wang X; Lu S; Dong Z
Clin Cancer Res; 2007 Oct; 13(19):5692-702. PubMed ID: 17908958
[TBL] [Abstract][Full Text] [Related]
11. Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer.
Tomlins SA; Laxman B; Dhanasekaran SM; Helgeson BE; Cao X; Morris DS; Menon A; Jing X; Cao Q; Han B; Yu J; Wang L; Montie JE; Rubin MA; Pienta KJ; Roulston D; Shah RB; Varambally S; Mehra R; Chinnaiyan AM
Nature; 2007 Aug; 448(7153):595-9. PubMed ID: 17671502
[TBL] [Abstract][Full Text] [Related]
12. Tumor-specific adenovirus-mediated PUMA gene transfer using the survivin promoter enhances radiosensitivity of breast cancer cells in vitro and in vivo.
Wang R; Wang X; Li B; Lin F; Dong K; Gao P; Zhang HZ
Breast Cancer Res Treat; 2009 Sep; 117(1):45-54. PubMed ID: 18791823
[TBL] [Abstract][Full Text] [Related]
13. Promoter hypermethylation of the SFRP2 gene is a high-frequent alteration and tumor-specific epigenetic marker in human breast cancer.
Veeck J; Noetzel E; Bektas N; Jost E; Hartmann A; Knüchel R; Dahl E
Mol Cancer; 2008 Nov; 7():83. PubMed ID: 18990230
[TBL] [Abstract][Full Text] [Related]
14. ErbB-2 induces the cyclin D1 gene in prostate epithelial cells in vitro and in vivo.
Casimiro M; Rodriguez O; Pootrakul L; Aventian M; Lushina N; Cromelin C; Ferzli G; Johnson K; Fricke S; Diba F; Kallakury B; Ohanyerenwa C; Chen M; Ostrowski M; Hung MC; Rabbani SA; Datar R; Cote R; Pestell R; Albanese C
Cancer Res; 2007 May; 67(9):4364-72. PubMed ID: 17483350
[TBL] [Abstract][Full Text] [Related]
15. Androgen receptor-dependent regulation of Bcl-xL expression: Implication in prostate cancer progression.
Sun A; Tang J; Hong Y; Song J; Terranova PF; Thrasher JB; Svojanovsky S; Wang HG; Li B
Prostate; 2008 Mar; 68(4):453-61. PubMed ID: 18196538
[TBL] [Abstract][Full Text] [Related]
16. Oncogenic activation of the human Pygopus2 promoter by E74-like factor-1.
Andrews PG; Kennedy MW; Popadiuk CM; Kao KR
Mol Cancer Res; 2008 Feb; 6(2):259-66. PubMed ID: 18314487
[TBL] [Abstract][Full Text] [Related]
17. Tumor-specific RNAi targeting eIF4E suppresses tumor growth, induces apoptosis and enhances cisplatin cytotoxicity in human breast carcinoma cells.
Dong K; Wang R; Wang X; Lin F; Shen JJ; Gao P; Zhang HZ
Breast Cancer Res Treat; 2009 Feb; 113(3):443-56. PubMed ID: 18327707
[TBL] [Abstract][Full Text] [Related]
18. Hypoxia-induced epithelial VEGF-C/VEGFR-3 upregulation in carcinoma cell lines.
Simiantonaki N; Jayasinghe C; Michel-Schmidt R; Peters K; Hermanns MI; Kirkpatrick CJ
Int J Oncol; 2008 Mar; 32(3):585-92. PubMed ID: 18292935
[TBL] [Abstract][Full Text] [Related]
19. [The efficacy of autocatalytic casapse-3 driven by human telomerase reverse transcriptase promoter on human ovarian carcinoma].
Song Y; Shen K; Yu JR
Zhonghua Yi Xue Za Zhi; 2007 Nov; 87(41):2919-24. PubMed ID: 18261307
[TBL] [Abstract][Full Text] [Related]
20. The extracellular matrix protein ITIH5 is a novel prognostic marker in invasive node-negative breast cancer and its aberrant expression is caused by promoter hypermethylation.
Veeck J; Chorovicer M; Naami A; Breuer E; Zafrakas M; Bektas N; Dürst M; Kristiansen G; Wild PJ; Hartmann A; Knuechel R; Dahl E
Oncogene; 2008 Jan; 27(6):865-76. PubMed ID: 17653090
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]